Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Vaccine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.VACCINE.2003.08.037PMID 14741159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative RT-PCR assay for HPV infection in cultured cells.

  2003cited by this paper
• Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein

  2002cited by this paper
• Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR

  2002cited by this paper
• A controlled trial of a human papillomavirus type 16 vaccine.

  2002cited by this paper
• HPV vaccine moves into late stage trials

  2001cited by this paper
• Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

  2001cited by this paper
• Immunological analyses of human papillomavirus capsids.

  2001cited by this paper
• Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.

  2001cited by this paper
• Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

  2000cited by this paper
• Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report.

  2000cited by this paper
• Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

  2000cited by this paper
• Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.

  2000cited by this paper
• Human papillomavirus vaccines.

  1999cited by this paper
• Common Neutralization Epitope in Minor Capsid Protein L2 of Human Papillomavirus Types 16 and 6

  1999cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999cited by this paper
• Estimates of the worldwide incidence of 25 major cancers in 1990

  1999cited by this paper
• Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies

  1998cited by this paper
• In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16

  1998cited by this paper
• Infectious human papillomavirus type 18 pseudovirions.

  1998cited by this paper
• A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.

  1998cited by this paper
• A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease.

  1997cited by this paper
• Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions.

  1997cited by this paper
• Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4.

  1997cited by this paper
• Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.

  1996cited by this paper
• Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus

  1996cited by this paper
• Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition

  1996cited by this paper
• Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

  1995cited by this paper
• Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection

  1995cited by this paper
• Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2.

  1995cited by this paper
• Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

  1995cited by this paper
• Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4.

  1995cited by this paper
• Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes.

  1995cited by this paper
• Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro.

  1995cited by this paper
• Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective

  1995cited by this paper
• Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.

  1994cited by this paper
• Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.

  1994cited by this paper
• Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.

  1994cited by this paper
• Generating the antibody repertoire in rabbit.

  1994cited by this paper
• Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles

  1993cited by this paper
• Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles

  1993cited by this paper
• Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins

  1993cited by this paper
• Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33

  1993cited by this paper
• Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

  1992cited by this paper
• Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.

  1992cited by this paper
• Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

  1991cited by this paper
• The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes.

  1991cited by this paper
• Human xenografts. A model system for human papillomavirus infection.

  1990cited by this paper
• Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11

  1990cited by this paper
• Human xenografts. A model system for human papillomavirus infection.

  1990cited by this paper
• Antibody-mediated neutralization in vivo of infectious papillomaviruses

  1990cited by this paper
• Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line

  1988cited by this paper
• Laboratory production in vivo of infectious human papillomavirus type 11

  1987cited by this paper

• Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

  2018cites this paper
• Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.

  2015cites this paper
• Papillomavirus Infectious Pathways: A Comparison of Systems

  2015cites this paper
• Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection

  2015cites this paper
• Development of prophylactic human papillomavirus vaccines

  2014cites this paper
• Broadly Protective Multimeric L2 Vaccine Phylogenetic Considerations in Designing a

  2014cites this paper
• A Vaccine of L2 Epitope Repeats Fused with a Modified IgG1 Fc Induced Cross-Neutralizing Antibodies and Protective Immunity against Divergent Human Papillomavirus Types

  2014cites this paper
• Diversity in Papillomavirus Host Interactions During Attachment and Entry

  2013cites this paper
• Phylogenetic Considerations in Designing a Broadly Protective Multimeric L2 Vaccine

  2013cites this paper
• Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.

  2012cites this paper
• The S100A10 Subunit of the Annexin A2 Heterotetramer Facilitates L2-Mediated Human Papillomavirus Infection

  2012cites this paper
• Study of infectious virus production from HPV18/16 capsid chimeras.

  2010cites this paper
• Replication and Assembly of Human Papillomaviruses

  2009cites this paper
• Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines

  2009cites this paper
• HPV as a model for the development of prophylactic and therapeutic cancer vaccines.

  2009cites this paper
• Arrangement of L2 within the Papillomavirus Capsid

  2008cites this paper
• Human Papillomavirus Type 16 Capsid Proteins: Immunogenicity and Possible Use as Prophylactic Vaccine Antigens

  2008cites this paper
• Vaccines against human papillomavirus.

  2007cites this paper
• Prevention and Treatment of Cervical Cancer by Vaccination

  2007cites this paper
• The Humoral Immune Response to Human Papillomavirus

  2007cites this paper
• Preventive and therapeutic HPV vaccines.

  2007cites this paper
• Current and Future HPV Vaccines : Promise and Challenges 2006

  2007cites this paper
• A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2

  2007cites this paper
• Opportunities to improve the prevention and treatment of cervical cancer.

  2007cites this paper
• Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes.

  2006cites this paper